Summary
Global Markets Direct’s, ‘Birch Pollen Allergy - Pipeline Review, H2 2016’, provides an overview of the Birch Pollen Allergy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
- The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
HAL Allergy BV
Stallergenes SAS
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Birch Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Birch Pollen Allergy - Overview 7
Birch Pollen Allergy - Therapeutics under Development by Companies 8
Birch Pollen Allergy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Birch Pollen Allergy - Products under Development by Companies 12
Birch Pollen Allergy - Companies Involved in Therapeutics Development 13
ALK-Abello A/S 13
Allergopharma GmbH & Co. KG 14
Anergis SA 15
Biomay AG 16
Circassia Pharmaceuticals Plc 17
HAL Allergy BV 18
Stallergenes SAS 19
Birch Pollen Allergy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AllerT - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Birch Pollen Allergoid - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BM-31 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
PL-102 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
STG-210 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Vaccine for Birch Pollen Allergy - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Birch Pollen Allergy - Dormant Projects 37
Birch Pollen Allergy - Discontinued Products 38
Birch Pollen Allergy - Product Development Milestones 39
Featured News & Press Releases 39
Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016 39
Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial 40
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen 40
Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting 41
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 41
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 42
May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen 42
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 43
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 43
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT 44
Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 44
Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT 45
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment 45
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen 46
Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Number of Products under Development for Birch Pollen Allergy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016 13
Birch Pollen Allergy - Pipeline by Allergopharma GmbH & Co. KG, H2 2016 14
Birch Pollen Allergy - Pipeline by Anergis SA, H2 2016 15
Birch Pollen Allergy - Pipeline by Biomay AG, H2 2016 16
Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 17
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016 18
Birch Pollen Allergy - Pipeline by Stallergenes SAS, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Birch Pollen Allergy - Dormant Projects, H2 2016 37
Birch Pollen Allergy - Discontinued Products, H2 2016 38
List of Figures
Number of Products under Development for Birch Pollen Allergy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24
